Τίτλος:
Immunotherapy in HER2-Positive Breast Cancer: A Systematic Review
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Introduction: The clinical outcome of HER2-positive breast cancer patients changed with the use of anti-Her therapies, though it still remains an aggressive and fatal disease. Implementation of immune checkpoint inhibitors in HER2-positive Breast cancer is a concept supported by the reported biological and preclinical data. Methods: We conducted a systematic review of the current literature involving immune checkpoint inhibitors alone or in combination with targeted therapies or chemotherapy finalized or running in HER2-positive breast cancer. Results: Twelve clinical trials and 2 case reports were identified in our study. Conclusion: The reported clinical trials highlight that checkpoint inhibition seems to be promising in metastatic, neoadjuvant, and adjuvant settings of HER2-positive breast cancer. © 2021 S. Karger AG, Basel. Copyright: All rights reserved.
Συγγραφείς:
Kyriazoglou, A.
Kaparelou, M.
Goumas, G.
Liontos, M.
Zakopoulou, R.
Zografos, E.
Zygogianni, A.
Dimopoulos, M.A.
Zagouri, F.
Λέξεις-κλειδιά:
anthracycline; atezolizumab; avelumab; cemiplimab; cyclophosphamide; cytotoxic T lymphocyte antigen 4; docetaxel; doxorubicin; durvalumab; epidermal growth factor receptor 2; immune checkpoint inhibitor; ipilimumab; nivolumab; paclitaxel; pembrolizumab; pertuzumab; progesterone; programmed death 1 ligand 1; programmed death 1 receptor; rituximab; ticilimumab; trastuzumab; trastuzumab emtansine; utomilumab, biological therapy; cancer growth; cancer immunotherapy; female; hormonal therapy; human; human epidermal growth factor receptor 2 positive breast cancer; neoadjuvant chemotherapy; overall survival; phase 2 clinical trial (topic); phase 3 clinical trial (topic); progression free survival; randomized controlled trial (topic); Review; systematic review; triple negative breast cancer; tumor microenvironment
